Hairy Cell Leukemia
📧 Sign up to get email alerts when something new happens for Hairy Cell Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia [Phase 2]
A Phase 2 trial sponsored by Scripps Health evaluated low-dose vemurafenib with rituximab for hairy cell leukemia. The study status is compl…
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies [Phase 2]
Phase 2 trial of Brexucabtagene Autoleucel in adults with rare B-cell malignancies has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies [Phase 1]
A Phase 1 trial evaluating flotetuzumab for relapsed or refractory CD123-positive hematologic malignancies has completed, providing initial …
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia [Phase 2]
Phase 2 trial results for the BRAF inhibitor vemurafenib in relapsed or refractory hairy cell leukemia have been completed and posted.
-
CLINICAL_TRIALS trial_result · 2025-08-08Clinical Trial Update: Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia [Phase 2]
Phase 2 trial evaluating cladribine given with simultaneous or delayed rituximab for hairy cell leukemia; results have been posted as of 202…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-07-18Clinical Trial Update: US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
A US post-marketing safety trial for LUMOXITI in hairy cell leukemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]
Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory …
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
A completed clinical trial investigated the role of large extracellular vesicles as biomarkers in various lymphomas and lymphoproliferative …
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab [Phase 2]
This update reports the results of a Phase 2 trial evaluating the combination of cladribine and rituximab for hairy cell leukemia and its va…
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
A long-term follow-up update on patients previously treated with Mustang Bio's CAR-T cell investigational product; the trial has been termin…
-
CLINICAL_TRIALS trial_result · 2024-05-01Clinical Trial Update: Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia [Phase 2]
A randomized Phase II trial comparing rituximab plus pentostatin versus rituximab plus bendamustine in multiply relapsed or refractory hairy…
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia [Phase 1]
Phase 1 trial evaluating moxetumomab pasudotox-tdfk (Lumoxiti) in combination with either rituximab (Rituxan) or the rituximab biosimilar Ru…
-
CLINICAL_TRIALS trial_result · 2019-04-05Clinical Trial Update: LMB-2 to Treat Hairy Cell Leukemia [Phase 2]
Phase 2 trial update for LMB-2 in hairy cell leukemia; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-04-02Clinical Trial Update: A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia [Phase 1]
Phase I multicenter dose-escalation study in patients with Hairy Cell Leukemia completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2018-08-27Clinical Trial Update: Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia [Phase 3]
Phase 3 trial update for moxetumomab pasudotox in advanced hairy cell leukemia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-07-19Clinical Trial Update: Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
This Clinical Trial Update describes a study collecting and storing malignant and related samples from young cancer patients; the trial stat…
-
CLINICAL_TRIALS trial_result · 2017-08-11Clinical Trial Update: Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease
The clinical trial evaluated the BRAF V600E mutation status in chronic lymphoproliferative diseases, specifically hairy cell leukemia and sp…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab in patients undergoing donor peripheral blood stem cell transplantation for relapsed or refractory B-cell…
-
CLINICAL_TRIALS trial_result · 2015-04-29Clinical Trial Update: Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia [Phase 1]
The document provides an update on the completion of a Phase 1 clinical trial evaluating immunotoxin therapy in patients with hairy cell leu…
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma [Phase 1]
Phase 1 study evaluating a combination of alvocidib, fludarabine phosphate, and rituximab in various B-cell lymphoproliferative disorders, w…
-
CLINICAL_TRIALS trial_result · 2012-05-15Clinical Trial Update: Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia [Phase 3]
A Phase 3 trial evaluating daily versus weekly dosing of cladribine for hairy cell leukemia has completed, reporting results on dosing sched…
-
CLINICAL_TRIALS trial_result · 2012-05-15Clinical Trial Update: Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy [Phase 2]
Phase 2 trial evaluating Rituximab in patients with refractory or recurrent hairy cell leukemia after cladribine therapy has completed.
-
CLINICAL_TRIALS trial_result · 2012-05-01Clinical Trial Update: Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia [Phase 2]
Phase 2 retreatment trial of BL22 immunotherapy in patients with relapsed or refractory Hairy Cell Leukemia was terminated, with results pos…
-
CLINICAL_TRIALS trial_result · 2011-02-21Clinical Trial Update: Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia
This completed clinical trial evaluated a method to detect residual disease in blood and bone marrow of patients with previously treated hai…
-
CLINICAL_TRIALS trial_result · 2010-06-22Clinical Trial Update: BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia [Phase 2]
Phase 2 clinical trial of BL22 immunotoxin in hairy cell leukemia patients previously treated with cladribine has completed.